Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Xortx Therapeutics is set to explore XRx-101, a formulation of Oxypurinol, as a potential treatment for acute kidney and lung injury associated with Covid-19.
Analysis of recent studies revealed that the most severe Covid-19 cases are characterised by acute kidney injury and acute pulmonary injury.
Furthermore, coronavirus infections involve pneumonia, acute kidney injury, proteinuria and haematuria. Based on the studies, Xortx Therapeutics believes that XRx-101 possesses the potential for front-line treatment of severe coronavirus cases while reducing morbidity and mortality in hospitalised patients.